Levocetirizine
- Generic Name
- Levocetirizine
- Brand Names
- Xyzal
- Drug Type
- Small Molecule
- Chemical Formula
- C21H25ClN2O3
- CAS Number
- 130018-77-8
- Unique Ingredient Identifier
- 6U5EA9RT2O
- Background
Levocetirizine is a selective histamine H antagonist used to treat a variety of allergic symptoms. It is the R enantiomer of cetirizine. Levocetirizine has greater affinity for the histamine H receptor than cetirizine.
Levocetirizine was granted FDA approval in 1995.
- Indication
Levocetirizine is indicated to treat symptoms of perennial allergic rhinitis and uncomplicated skin manifestations of chronic idiopathic urticaria. It is also used over the counter for a variety of mild allergy symptoms.
- Associated Conditions
- Allergic Rhinitis (AR), Chronic Idiopathic Urticaria, Common Cold, Nasal Congestion, Perennial Allergic Rhinitis (PAR), Seasonal Allergic Rhinitis
- Associated Therapies
- -
Singapore's CBC and Mubadala acquired UCB's Chinese division for $680 million
CBC Group, Singapore's largest healthcare company, completed the acquisition of UCB's Chinese biopharmaceutical division for $680 million, in partnership with Mubadala Investment Company. The deal includes brands like UCB Keppra, Vimpat, Neupro, Zyrtec, Xyzal, and a production site in Zhuhai. The new company, NeuroGen Pharma, aims to become the largest neurology company in China, leveraging CBC and Mubadala's innovations in neurosurgery.
Focuses on New Launch and Completes Divestment of Mature Product Business in China
UCB sold its mature neurology and allergy portfolio in China, including Keppra®, Vimpat®, Neupro®, Zyrtec®, Xyzal®, and the Zhuhai manufacturing facility, to CBC Group and Mubadala Investment Company for $680 million. The portfolio will be transferred to NeuroGen Pharma, a new CNS-focused company. UCB also entered a commercialization agreement with Bioray to bring Bimzelx® to Chinese patients, shifting its strategy to focus on novel therapies.
France warns of penalties if Opella production goes offshore
Sanofi in exclusive talks with Clayton Dubilier & Rice to sell a 50% stake in Opella, valued at €16 billion. French government demands production, R&D, management, and workforce remain in France, with €70 million investment commitment. Sanctions include €40 million fine for closing facilities and €100,000 per layoff. France to take 2% stake in Opella. CD&R outbid PAI Partners, raising concerns over job security.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath